Unique lipid cargoes in APOE4 human brain-derived extracellular vesicles recruit cell adhesion molecules and promote tauopathy in Alzheimer's disease., PMID:40502793
Anti-Amyloid Agents: A Self-Fulfilling prophecy., PMID:40393205
The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis., PMID:40316479
Discovery of an ApoE4-targeted small-molecule SirT1 enhancer for the treatment of Alzheimer's disease., PMID:40269061
Conformational features of guinea pig apolipoprotein E offer insights into functioning of human apolipoprotein E., PMID:40221014
A Quantitative Trait Locus for Reduced Microglial APOE Expression Associates with Reduced Cerebral Amyloid Angiopathy., PMID:40162256
Exploring epidemiological risk factors for cerebral amyloid angiopathy: Considerations for monoclonal antibody therapy in people with Alzheimer's disease., PMID:40042470
Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics., PMID:40011173
Evaluation of two plasma-based proteotyping assays against APOE ε4 genotyping in a memory clinic setting: The Gothenburg H70 Clinical Studies., PMID:39988952
The impact of apolipoprotein E, type ∊4 allele on Alzheimer's disease pathological biomarkers: a comprehensive post-mortem pilot-analysis., PMID:39913635
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease., PMID:39800458
Brain MRI volumetry and atrophy rating scales as predictors of amyloid status and eligibility for anti-amyloid treatment in a real-world memory clinic setting., PMID:39708177
Insights into the transcriptomic heterogeneity of brain endothelial cells in normal aging and Alzheimer's disease., PMID:39688567
Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: A systematic review and meta-analysis., PMID:39638097
Initial Experience with Lecanemab and Lessons Learned in 71 Patients in a Regional Medical Center., PMID:39559868
Alzheimer's disease-linked risk alleles elevate microglial cGAS-associated senescence and neurodegeneration in a tauopathy model., PMID:39353433
In 2024, the amyloid-cascade-hypothesis still remains a working hypothesis, no less but certainly no more., PMID:39295642
Advancements in APOE and dementia research: Highlights from the 2023 AAIC Advancements: APOE conference., PMID:39031528
Drugs targeting APOE4 that regulate beta-amyloid aggregation in the brain: Therapeutic potential for Alzheimer's disease., PMID:39020526
Temporal Characterization of the Amyloidogenic APPswe/PS1dE9;hAPOE4 Mouse Model of Alzheimer's Disease., PMID:38891941
Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer's disease., PMID:38824138
Three major effects of APOEε4 on Aβ immunotherapy induced ARIA., PMID:38756535
Human in vivo evidence of associations between herpes simplex virus and cerebral amyloid-beta load in normal aging., PMID:38570885
APOE and Alzheimer's disease: Pathologic clues from transgenic Drosophila melanogaster., PMID:38537387
Generation of novel anti-apoE monoclonal antibodies that selectively recognize apoE isoforms., PMID:38529702
Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer Disease., PMID:38484190
Letter to the Editor: Alzheimer's Disease-Associated APOE ε4 Frequencies in Indian Population Genomes May Suggest Implications in Lecanemab Treatment., PMID:38374759
Herpes Simplex Viral Infection Doubles the Risk of Dementia in a Contemporary Cohort of Older Adults: A Prospective Study., PMID:38306033
Apolipoprotein E secreted by astrocytes forms antiparallel dimers in discoidal lipoproteins., PMID:38266643
Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies., PMID:38165296
Association of Apolipoprotein E Gene Polymorphism with Type 2 Diabetic Nephropathy in the Southern Chinese Population., PMID:38034901
Imaging of Amyloid-Related Imaging Abnormalities (ARIA)., PMID:37995736
Serum immunoglobulins and biomarkers of dementia: a population-based study., PMID:37936180
APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry., PMID:37930705
ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels., PMID:37930695
APOE Genotype in the Era of Disease-Modifying Treatment With Monoclonal Antibodies Against Amyloid-β., PMID:37930662
FSH and ApoE4 contribute to Alzheimer's disease-like pathogenesis via C/EBPβ/δ-secretase in female mice., PMID:37852961
Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer's Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion., PMID:37812325
APOE Christchurch-mimetic therapeutic antibody reduces APOE-mediated toxicity and tau phosphorylation., PMID:37791598
APOE4 impairs the microglial response in Alzheimer's disease by inducing TGFβ-mediated checkpoints., PMID:37749326
Lecanemab: Appropriate Use Recommendations., PMID:37357276
Plasma biomarkers for prediction of Alzheimer's disease neuropathologic change., PMID:37269398
APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trials., PMID:37204338
ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease., PMID:36949897
Neutrophils as a potential therapeutic target in Alzheimer's disease., PMID:36936930
Astrocytic APOE4 removal confers cerebrovascular protection despite increased cerebral amyloid angiopathy., PMID:36922879
Plasma IAPP-Autoantibody Levels in Alzheimer's Disease Patients Are Affected by APOE4 Status., PMID:36835187
Isoform-specific modification of apolipoprotein E by 4-hydroxynonenal: protective role of apolipoprotein E3 against oxidative species., PMID:36661393
Alzheimer's drug stirs excitement-and concerns., PMID:36480604
For research use only. Not for human or drug use.
